Key takeaways from ASCO® 2026
July 16, 2026 |
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they examine the evolving role of congresses, from experience design and technology to strategy, measurement and commercial impact.
What the best congress experiences got right at ASCO® 2026
Simon Davenport, Global Head of Environments at Inizio Engage, explores the characteristics that set the most successful congress experiences apart. Drawing on observations from the exhibition floor, the article highlights three key principles: creating a clear and consistent scientific narrative, designing interactions that genuinely enhance engagement rather than relying on technology for its own sake, and building flexible experiences that allow HCPs to engage at different levels. The article explains why thoughtful experience design is becoming increasingly important as congress environments grow more competitive.
Read full article here.
What ASCO® 2026 revealed about the future of pharma congress engagement
Nick Bellomo, VP of Experience and Technology at Inizio Medical, examines the technology and engagement innovations that stood out across ASCO® 2026. From immersive LED environments and AI-powered interactions to tactile, low-tech activations, the article explores how organisations are rethinking the use of technology to create more meaningful scientific engagement. It concludes that the most effective congress experiences combine creativity with purposeful design to strengthen scientific communication and generate valuable behavioural insights.
Read full article here.
ASCO® 2026: Why a connected approach is key to congress success
Lynsey Holbrook, Global Client Development Director at Inizio Engage, focuses on the growing complexity of congress planning and the challenge of demonstrating return on investment. The article explores why many pharmaceutical organisations struggle to connect strategy, execution and measurement, despite increasing investment in congresses. It outlines how a more connected approach can help teams align stakeholders, create more coordinated delegate experiences and measure the activities that drive meaningful scientific and commercial outcomes.
Read full article here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Market Insights Can Deliver a Better Patient Experience
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Excellence in oncology: Developing an effective biomarker strategy
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus’s Approach to Measurement Wins 3 Gold’s at 2014 AMEC International Summit in Amsterdam
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Pegasus Crowned Health Consultancy of the Year at 2014 Sabre Emea Awards
Brighton consultancy adds top honour to its award wins
Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Pegasus Moves to Brighton
Top UK Healthcare Communications Consultancy Moves to Brighton
Warehousing of HCV patients reaches new high
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Brand leaders in RA will lose market share, predict rheumatologists
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
Removing the Roadblocks to Effective Patient Treatment
How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from…
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards…